USANA Health Sciences Q3 sales fall 4%, cuts full year outlook

Overview

• Nutritional supplement maker's Q3 net sales fell 4% yr/yr on lower Core and Rise sales

• Company posted Q3 net loss of $5.6 mln

• Hiya active subscribers rose 18% sequentially; Core Nutritional margin expanded despite lower sales

Outlook

• Company lowers 2026 consolidated net sales outlook to approaching $900 mln from $910 mln

• Company cuts 2026 adjusted EBITDA forecast to $77 mln from $80.5 mln

• Company says lower outlook reflects reduced Rise Wellness expectations and increased investment in Hiya

Result Drivers

• HIYA MARKETING SPEND - Co increased marketing at Hiya, boosting active subscribers 18% sequentially but weighing on margins

• LEANER COST STRUCTURE - Core Nutritional margin expanded due to leaner cost structure despite lower net sales

• ACTIVE CUSTOMER INITIATIVES - Co said initiatives in Southeast Asia Pacific helped drive 3% sequential growth in active customers

Company press release:

Key Details

Analyst Coverage

• Wall Street's median 12-month price target for USANA Health Sciences Inc is $25.00, about 69.8% above its November 2 closing price of $14.72

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads

• Nov 2 - Herbalife's Q3 results beat estimates on Asia-Pacific sales growth; lifts FY outlook

• Nov 3 - Vital Farms Q3 revenue misses estimates; cuts FY forecast

• Nov 2 - Gaia Q3 revenue falls 12% but beats analyst expectations

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)